Assessment of the global and national market for lipid modifying agents: retrospective and innovation
Lipid-lowering therapy is one of the most important aspects in the treatment of patients with cardiovascular disease, which is still the leading cause of death in the adult population. Over the past 10 years, fundamentally new lipid-lowering drugs have appeared such as alipogene tiparvovec, mipomers...
Main Authors: | A. V. Lokhmacheva, S. G. Fominykh, L. V. Trubina, I. E. Sikhvardt |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Russian Academy of Sciences, Siberian Branch Publishing House
2023-08-01
|
Series: | Сибирский научный медицинский журнал |
Subjects: | |
Online Access: | https://sibmed.elpub.ru/jour/article/view/1154 |
Similar Items
-
Network Meta‐Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid‐Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low‐Density Lipoprotein Cholesterol
by: Peter P. Toth, et al.
Published: (2022-09-01) -
Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
by: Chandni Bardolia, et al.
Published: (2021-11-01) -
New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy
by: S. K. Zyryanov, et al.
Published: (2022-12-01) -
The wind of change – PCSK9 inhibitors in hypolipidemic treatment. The Polish perspective
by: Natalia Ilnicka, et al.
Published: (2023-09-01) -
Xanthomas Regression in an 8-Year-Old Boy Treated With Lomitapide
by: Genovefa Kolovou, MD, PhD, et al.
Published: (2019-10-01)